ExodusPoint Capital Management’s Immunogen Inc IMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-38,733
Closed -$615K 2173
2023
Q3
$615K Buy
+38,733
New +$644K 0.01% 1166
2023
Q2
Sell
-31,268
Closed -$120K 2349
2023
Q1
$120K Buy
+31,268
New +$133K ﹤0.01% 1621
2022
Q4
Sell
-360,717
Closed -$1.72M 2266
2022
Q3
$1.72M Buy
360,717
+209,281
+138% +$1.1M 0.02% 868
2022
Q2
$681K Buy
151,436
+731
+0.5% +$3.18K 0.01% 1242
2022
Q1
$717K Buy
150,705
+108,428
+256% +$600K 0.01% 1340
2021
Q4
$314K Sell
42,277
-253,725
-86% -$1.58M ﹤0.01% 1643
2021
Q3
$1.68M Buy
296,002
+179,536
+154% +$1.04M 0.02% 795
2021
Q2
$768K Buy
116,466
+20,326
+21% +$142K 0.01% 1129
2021
Q1
$779K Buy
96,140
+75,940
+376% +$620K 0.01% 1069
2020
Q4
$130K Sell
20,200
-58,813
-74% -$343K ﹤0.01% 1802
2020
Q3
$284K Buy
79,013
+68,646
+662% +$277K 0.01% 1318
2020
Q2
$48K Sell
10,367
-33,271
-76% -$142K ﹤0.01% 1685
2020
Q1
$149K Buy
+43,638
New +$191K 0.01% 839

Other funds holding IMGN

ExodusPoint Capital Management's IMGN Position: Q4 2023 in Review

ExodusPoint Capital Management sold out of Immunogen Inc (IMGN) in Q4 2023, closing a stake of 38,733 shares — an estimated $615K sold.

ExodusPoint Capital Management first reported a position in IMGN in Q1 2020 and held it in 13 quarters. The position peaked at $1.72M in Q3 2022. 327 funds tracked by Wall St. Rank hold IMGN as of Q4 2023.

  • ExodusPoint Capital Management reported no remaining Immunogen Inc position as of Q4 2023 after selling out during the quarter.
  • ExodusPoint Capital Management sold 38,733 Immunogen Inc shares in Q4 2023, an estimated $615K.
  • ExodusPoint Capital Management first reported a position in Immunogen Inc in Q1 2020 and held it in 13 quarters.
  • ExodusPoint Capital Management's Immunogen Inc position peaked at $1.72M in Q3 2022.
  • 327 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2023.

Based on ExodusPoint Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.